In adults with systolic blood pressure >140 mm Hg taking 2 or more antihypertensives[1a],[2a],[3a]

Doctor walking a Lion-heart across the screen to indicate control Doctor walking a Lion-heart across the screen to indicate control

In adults with systolic blood pressure >140 mm Hg taking 2 or more antihypertensives[1a],[2a],[3a]

AIM TOCONTROLTHE UNCONTROLLABLEIN HYPERTENSION[1b],[2b],[3b]

THE FIRST AND ONLY FDA-APPROVED ALDOSTERONE SYNTHASE INHIBITOR BAXFENDY DELIVERED double-digit absolute reductions in systolic blood pressure in adults who were not adequately controlled on other agents[1c],[2c],[3c]

Light Bulb Icon

Learn more about how BAXFENDY, the first & only FDA-approved aldosterone synthase inhibitor, treats hypertension differently[1d]

See how it works

Abbreviations: FDA=Food and Drug Administration; MOA=mechanism of action.

References:

  1. 1a 1b 1c 1d BAXFENDY® (baxdrostat) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2026.
  2. 2a 2b 2c Flack JM, Azizi M, Brown JM, et al; BaxHTN Investigators. Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension [including online supplement]. N Engl J Med. 2025;393(14):1363-1374.
  3. 3a 3b 3c Azizi M, Brown JM, Dwyer JP, et al; Bax24 investigators. Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial [including online supplement]. Lancet. 2026;407(10532):988-999.